These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 29670173)

  • 1. Overexpression of HER2 in the pancreas promotes development of intraductal papillary mucinous neoplasms in mice.
    Shibata W; Kinoshita H; Hikiba Y; Sato T; Ishii Y; Sue S; Sugimori M; Suzuki N; Sakitani K; Ijichi H; Mori R; Endo I; Maeda S
    Sci Rep; 2018 Apr; 8(1):6150. PubMed ID: 29670173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas.
    Furukawa T; Fujisaki R; Yoshida Y; Kanai N; Sunamura M; Abe T; Takeda K; Matsuno S; Horii A
    Mod Pathol; 2005 Aug; 18(8):1034-42. PubMed ID: 15832194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular mechanism of intraductal papillary mucinous neoplasm and intraductal papillary mucinous neoplasm-derived pancreatic ductal adenocarcinoma.
    Fukuda A
    J Hepatobiliary Pancreat Sci; 2015 Jul; 22(7):519-23. PubMed ID: 25900667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
    Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
    Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological significance of somatic RNF43 mutation and aberrant expression of ring finger protein 43 in intraductal papillary mucinous neoplasms of the pancreas.
    Sakamoto H; Kuboki Y; Hatori T; Yamamoto M; Sugiyama M; Shibata N; Shimizu K; Shiratori K; Furukawa T
    Mod Pathol; 2015 Feb; 28(2):261-7. PubMed ID: 25081753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular genetics of intraductal papillary-mucinous neoplasms of the pancreas.
    Furukawa T
    J Hepatobiliary Pancreat Surg; 2007; 14(3):233-7. PubMed ID: 17520197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinction of Invasive Carcinoma Derived From Intraductal Papillary Mucinous Neoplasms From Concomitant Ductal Adenocarcinoma of the Pancreas Using Molecular Biomarkers.
    Tamura K; Ohtsuka T; Date K; Fujimoto T; Matsunaga T; Kimura H; Watanabe Y; Miyazaki T; Ohuchida K; Takahata S; Ishigami K; Oda Y; Mizumoto K; Nakamura M; Tanaka M
    Pancreas; 2016 Jul; 45(6):826-35. PubMed ID: 26646266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel xenograft and cell line derived from an invasive intraductal papillary mucinous neoplasm of the pancreas give new insights into molecular mechanisms.
    Fritz S; Fernández-del Castillo C; Iafrate AJ; Mino-Kenudson M; Neyhard N; LaFemina J; Stirman A; Warshaw AL; Thayer SP
    Pancreas; 2010 Apr; 39(3):308-14. PubMed ID: 19924021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The chromatin regulator Brg1 suppresses formation of intraductal papillary mucinous neoplasm and pancreatic ductal adenocarcinoma.
    von Figura G; Fukuda A; Roy N; Liku ME; Morris Iv JP; Kim GE; Russ HA; Firpo MA; Mulvihill SJ; Dawson DW; Ferrer J; Mueller WF; Busch A; Hertel KJ; Hebrok M
    Nat Cell Biol; 2014 Mar; 16(3):255-67. PubMed ID: 24561622
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Collet L; Ghurburrun E; Meyers N; Assi M; Pirlot B; Leclercq IA; Couvelard A; Komuta M; Cros J; Demetter P; Lemaigre FP; Borbath I; Jacquemin P
    Gut; 2020 Apr; 69(4):704-714. PubMed ID: 31154393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The immunohistochemical mucin expression pattern distinguishes different types of intraductal papillary mucinous neoplasms of the pancreas and determines their relationship to mucinous noncystic carcinoma and ductal adenocarcinoma.
    Lüttges J; Zamboni G; Longnecker D; Klöppel G
    Am J Surg Pathol; 2001 Jul; 25(7):942-8. PubMed ID: 11420467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraductal papillary mucinous carcinoma with co-mutations of
    Nagao M; Ueo T; Fukuda A; Ohana M
    BMJ Case Rep; 2023 Nov; 16(11):. PubMed ID: 38011945
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluation of KRAS Mutation Status in a Patient With Concomitant Pancreatic Neuroendocrine Neoplasm and Intraductal Papillary Mucinous Neoplasm.
    Igarashi T; Harimoto N; Nobusawa S; Yoshida Y; Yamanaka T; Hagiwara K; Hoshino K; Ishii N; Tsukagoshi M; Watanabe A; Kubo N; Araki K; Yokobori T; Yokoo H; Shirabe K
    Pancreas; 2019; 48(5):e34-e35. PubMed ID: 31090662
    [No Abstract]   [Full Text] [Related]  

  • 14. Tuft Cells Inhibit Pancreatic Tumorigenesis in Mice by Producing Prostaglandin D
    DelGiorno KE; Chung CY; Vavinskaya V; Maurer HC; Novak SW; Lytle NK; Ma Z; Giraddi RR; Wang D; Fang L; Naeem RF; Andrade LR; Ali WH; Tseng H; Tsui C; Gubbala VB; Ridinger-Saison M; Ohmoto M; Erikson GA; O'Connor C; Shokhirev MN; Hah N; Urade Y; Matsumoto I; Kaech SM; Singh PK; Manor U; Olive KP; Wahl GM
    Gastroenterology; 2020 Nov; 159(5):1866-1881.e8. PubMed ID: 32717220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pdcd4 expression in intraductal papillary mucinous neoplasm of the pancreas: its association with tumor progression and proliferation.
    Hayashi A; Aishima S; Miyasaka Y; Nakata K; Morimatsu K; Oda Y; Nagai E; Oda Y; Tanaka M; Tsuneyoshi M
    Hum Pathol; 2010 Nov; 41(11):1507-15. PubMed ID: 20656320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of adding GNAS testing to pancreatic cyst fluid KRAS and carcinoembryonic antigen analysis for the diagnosis of intraductal papillary mucinous neoplasms.
    Kadayifci A; Atar M; Wang JL; Forcione DG; Casey BW; Pitman MB; Brugge WR
    Dig Endosc; 2017 Jan; 29(1):111-117. PubMed ID: 27514845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pancreatic intraductal tubulopapillary neoplasm is genetically distinct from intraductal papillary mucinous neoplasm and ductal adenocarcinoma.
    Basturk O; Berger MF; Yamaguchi H; Adsay V; Askan G; Bhanot UK; Zehir A; Carneiro F; Hong SM; Zamboni G; Dikoglu E; Jobanputra V; Wrzeszczynski KO; Balci S; Allen P; Ikari N; Takeuchi S; Akagawa H; Kanno A; Shimosegawa T; Morikawa T; Motoi F; Unno M; Higuchi R; Yamamoto M; Shimizu K; Furukawa T; Klimstra DS
    Mod Pathol; 2017 Dec; 30(12):1760-1772. PubMed ID: 28776573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
    Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
    Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutational analyses of multiple oncogenic pathways in intraductal papillary mucinous neoplasms of the pancreas.
    Schönleben F; Allendorf JD; Qiu W; Li X; Ho DJ; Ciau NT; Fine RL; Chabot JA; Remotti HE; Su GH
    Pancreas; 2008 Mar; 36(2):168-72. PubMed ID: 18376308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreatic intraductal papillary mucinous neoplasm in a patient with Lynch syndrome.
    Flanagan MR; Jayaraj A; Xiong W; Yeh MM; Raskind WH; Pillarisetty VG
    World J Gastroenterol; 2015 Mar; 21(9):2820-5. PubMed ID: 25759555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.